s biotech too founder-friendly? Is honesty overrated? And how do you tell a good beep from a bad one?
We discuss all that and more on this week’s episode of “The Readout LOUD,” STAT’s biotech podcast. Tune in for a chat with Atlas Venture’s Bruce Booth about how biotech’s recent boom has changed the dynamic between VCs and entrepreneurs. Then we talk about the latest controversy surrounding doctors who take payments from the drug industry and fail to disclose them. And STAT’s Eric Boodman joins us to discuss why Medtronic reached out to an avant-garde electronic musician in the name of making medical devices more effective. And finally there’s a lightning round, featuring a unicorn IPO, a would-be Martin Shkreli, and the likely end of the CRISPR patent dispute.
For more on what we cover, here’s Bruce Booth’s blog post; here’s the news on conflict of interest; here’s the story on Medtronic’s musical adventure; and here’s the news about Moderna’s IPO plans.
We’ll be back next Thursday evening — and every Thursday evening — so be sure to sign up on iTunes, Stitcher, Google Play, or wherever you get your podcasts.
And if you have any feedback for us — topics to cover, guests to invite, vocal tics to cease — you can email email@example.com.
Interested in sponsoring a future episode of “The Readout LOUD”? Email us at firstname.lastname@example.org.